Tertiary lymphoid structures marker CXCL13 is associated with better survival for patients with advanced-stage bladder cancer treated with immunotherapy
Clarice S. Groeneveld, Jacqueline Fontugne, Luc Cabel, Isabelle Bernard‐Pierrot, François Radvanyi, Yves Allory, Aurélien de Reyniès
Topics & Concepts
ImmunotherapyCXCL13Bladder cancerMedicineStage (stratigraphy)OncologyCancer immunotherapyInternal medicineCancerImmunologyBiologyChemokineReceptorChemokine receptorPaleontologyBladder and Urothelial Cancer TreatmentsCancer Immunotherapy and BiomarkersChemokine receptors and signaling